Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esflurbiprofen transdermal - Teikoku Seiyaku

Next Previous
Drug Profile

Esflurbiprofen transdermal - Teikoku Seiyaku

Alternative Names: TK-254R; TK-254RX

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teikoku Seiyaku
  • Class Analgesics; Antirheumatics; Biphenyl compounds; Fluorobenzenes; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute pain

Most Recent Events

  • 17 Apr 2025 Teikoku Seiyaku initiates the phase I trial for Pain in Germany (Topical) (NCT06866613)
  • 14 Apr 2025 Teikoku Seiyaku completes a phase I trial for Acute pain in Germany (Topical) (NCT06870422) (EudraCT2024-513059-33-00)
  • 25 Mar 2025 Teikoku Seiyaku plans a phase III trial for Pain in Germany (Topical), in March 2025 (NCT06866613)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top